Katie Couric’s Post

Interesting move from AstraZeneca manufacturing and supply chains. Consider for a moment that in the full 2023 results, the US was 42% of global sales. Emerging Markets were 26%, Established Rest of World 11% and Europe 21%. Given the tensions between the US and China, this seems like a good business move to safeguard supply to 42% of AZ's sales. I don't know if other players are doing this or thinking of doing it. I always felt that from my time at AZ, we were ahead of the curve on so many business and commercial initiatives. The rest often followed. I will watch with interest how this move by AZ works out.

The Academic Society welcomes AbbVie with Sebastian Wachtarz as a new member of the Corporate Advisory Board! 🤝 Sebastian Wachtarz is Director Government & Public Affairs at AbbVie Germany and leads a team of 30 employees. He graduated from Universität Leipzig with a degree in Communications and Media Studies. AbbVie is a global biopharmaceutical company and has a total of 50,000 employees worldwide in more than 70 countries. 🌎 We asked Sebastian what he enjoys most about his position at AbbVie and got some insights into his personal and professional life. 💡 Read the full interview below 👇   #newpartnership #network #knowledgetransfer #corporatecommunications #communicationresearch

🤩 Exciting news! AstraZeneca, the global pharmaceutical and biotechnology company, has implemented OMP's Unison Planning™ as its new advanced planning system. This is a major milestone in their digital transformation journey toward enhanced quality, speed, and efficiency of medicine delivery to its patients. 👇 Read the full story for more details. #supplychain #biotech #digitaltransformation

Thoughts on this? >> AstraZeneca doubles down on China stronghold with focus on R&D, supply chain >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #healthcare #pharmaceutical

Last week, I participated in a panel discussion at the Science | Business Health Day hosted in Brussels titled “Competitive balance: How will Europe be positioned by 2030?”. We discussed how we can keep Europe competitive in the future both regarding the regulatory landscape and the supporting environment.  With upcoming changes to the pharmaceutical legislation in the EU, we have a golden opportunity to ensure we continue to provide competitive and meaningful benefits to patients.  This is the first major reform to the pharmaceutical legislation in two decades, and whatever is decided is expected to shape the industry for the next 20+ years.  For me there are several elements we need to focus on if we want to continue to be competitive.  We need to ensure an environment that values innovation, ensures inward investment and enhances a competent science, technology, engineering, and mathematics (STEM) workforce.  There also needs to be an ecosystem that allows larger pharmaceutical companies to collaborate with smaller and medium sized companies, this applies both to drug development partnerships and the acquisition of products and companies.

🤩 Exciting news! AstraZeneca, the global pharmaceutical and biotechnology company, has implemented OMP's Unison Planning™ as its new advanced planning system. This is a major milestone in their digital transformation journey toward enhanced quality, speed, and efficiency of medicine delivery to its patients. 👇 Read the full story for more details. #supplychain #biotech #digitaltransformation

Thoughts on this? >> AstraZeneca doubles down on China stronghold with focus on R&D, supply chain >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #pharma #biotech

🤩 Exciting news! AstraZeneca, the global pharmaceutical and biotechnology company, has implemented OMP's Unison Planning™ as its new advanced planning system. This is a major milestone in their digital transformation journey toward enhanced quality, speed, and efficiency of medicine delivery to its patients. 👇 Read the full story for more details. #supplychain #biotech #digitaltransformation